Peripheral neuropathy (PN) is one of the most significant unmet needs today, affecting 1 in 15 in the U.S. PN is the dying of nerves caused by many major diseases or injuries, e.g., diabetes, cancer/chemo, HIV, and genetic diseases. There is currently no treatment, only pain drugs that reduce all feeling. We are now in trials showing that we may be on track to reverse the disease, both biologically and functionally and, most importantly, to improve the quality-of-life for the millions affected.
CEO's prior two companies were acquired by Qualcomm and Apple, with technologies now standards in the industry.
Over $30M of non-dilutive funding (peer-reviewed grants rewarding innovation above 'hot' target trends) has driven the research and development.
Extensive evidence, including a proof-of-concept study in humans, showing a reversal of PN through 1) nerve regrowth, 2) reduced symptoms, and 3) return of quality-of-life to patients.
Having completed Phase 1 safety studies, we're entering Phase 2 early efficacy studies this year for our lead drug, WST-057, a study funded by the Canadian government.
The active ingredient in our drug is a historically safe drug used for 30+ years that is being 'recycled' to get to patients faster - increasing safety and lowering development cost and time.
Assemblage of nearly every stakeholder in diabetic peripheral neuropathy (DPN): clinicians, researchers, non-profits, governments, and, critically, patients.
To date, we have no outside investors. Our only true investors are our service providers, friends & family, and potential patients - all stakeholders who like where we are going.
The valuation of past companies attempting to treat DPN was several hundred million dollars after Phase 1 and several billion dollars after Phase 2.